Deciphering riddles in molecular subtyping of bladder cancer DOI Creative Commons
Yuxiao Li, Shan Huang, W. Ju

et al.

Asian journal of urology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Urinary Tract Cytopathology DOI
Mercè Jordà, Oleksandr N. Kryvenko,

Fiona Hanly

et al.

Surgical pathology clinics, Journal Year: 2024, Volume and Issue: 17(3), P. 383 - 394

Published: July 14, 2024

Language: Английский

Citations

2
The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer DOI Creative Commons
Tatiana Cano Barbadilla, Martina Álvarez, Juan Daniel Prieto Cuadra

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(22), P. 2501 - 2501

Published: Nov. 8, 2024

Bladder cancer (BC) is a highly heterogeneous disease, presenting clinical challenges, particularly in predicting patient outcomes and selecting effective treatments. Molecular subtyping has emerged as an essential tool for understanding the biological diversity of BC; however, its implementation practice remains limited due to high costs complexity genomic techniques. This review examines role immunohistochemistry (IHC) surrogate marker molecular BC, highlighting potential bridge gap between advanced classifications routine application; Methods: We explore evolution taxonomic classification with particular focus on cytokeratin (KRT) expression patterns normal urothelium, which are key identifying basal luminal subtypes. Furthermore, we emphasise need consensus IHC markers reliably define these subtypes, facilitating wider standardised use. The also analyses application both muscle-invasive (MIBC) non-muscle-invasive bladder (NMIBC), attention less extensively studied NMIBC cases. discuss practical advantages subtyping, including cost effectiveness feasibility standard pathology laboratories, alongside ongoing challenges such requirement protocols external validation across diverse settings; Conclusions: While limitations, it offers viable alternative laboratories lacking access Further research required determine optimal combination markers, establish diagnostic algorithm, validate through large-scale trials. will ultimately enhance accuracy, guide treatment decisions, improve outcomes.

Language: Английский

Citations

1
Prognostic impact of EGFR expression and immunohistochemistry-based “molecular classification” in bladder cancer DOI

Yusuf Onder Ozsagir,

Elif Özsağır, Eyüp Dil

et al.

Annals of Diagnostic Pathology, Journal Year: 2024, Volume and Issue: 73, P. 152380 - 152380

Published: Oct. 10, 2024

Language: Английский

Citations

0
Deciphering riddles in molecular subtyping of bladder cancer DOI Creative Commons
Yuxiao Li, Shan Huang, W. Ju

et al.

Asian journal of urology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

0